Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma
Broad Institute · Massachusetts General Hospital · +23 more institutions
Abstract
To explore the biology of lung adenocarcinoma (LUAD) and identify new therapeutic opportunities, we performed comprehensive proteogenomic characterization of 110 tumors and 101 matched normal adjacent tissues (NATs) incorporating genomics, epigenomics, deep-scale proteomics, phosphoproteomics, and acetylproteomics. Multi-omics clustering revealed four subgroups defined by key driver mutations, country, and gender. Proteomic and phosphoproteomic data illuminated biology downstream of copy number aberrations, somatic mutations, and fusions and identified therapeutic vulnerabilities associated with driver events involving KRAS, EGFR, and ALK. Immune subtyping revealed a complex landscape, reinforced the…
Citation impact
- FWCI
- 39.26
- Percentile
- 100%
- References
- 270
Authors
186- MAMichael A. GilletteCorresponding
Broad Institute, Massachusetts General Hospital, Massachusetts Institute of Technology
- SSShankha SatpathyCorresponding
Broad Institute, Massachusetts Institute of Technology
- SCSong Cao
Washington University in St. Louis
- SMSaravana M. Dhanasekaran
University of Michigan
- SVSuhas Vasaikar
The University of Texas MD Anderson Cancer Center
Topics & keywords
- Proteogenomics
- Biology
- Proteomics
- Computational biology
- Phosphoproteomics
- Adenocarcinoma
- Epigenomics
- Genomics
- Good health and well-being